Qlife Holding – Presentation of Q3 interim report 2022

Qlife Holding – Presentation of Q3 interim report 2022

Qlife Holding – Presentation of Q3 interim report 2022 30 NovemberNov 2022 13:00 - 13:30Online Event

Meet Qlife Holding’s CEO Thomas Warthoe and CFO Kasper Rousøe when they present the Q3 report.

The event takes place on the 30th  of November – at 13:00 CET.

We expect the event to last for 30 min including questions.

The focus will be on the Q3 report and the latest events including updates on the rights issue.

 

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarker and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases.

Qlife Holding was formed in October 2019 and received the certification ISO 13485:2016 the same year, which means that Qlife meets all requirements for the manufacture and sale of in-vitro diagnostic analyzers and reagents. The first capsules in the company's product, Egoo.Health Platform, was CE marked for professional use in early 2020. The company has patent protection for key parts of its technology.

Qlife Holding AB is listed on Nasdaq First North Stockholm with the ticker QLIFE.

Disclaimer: HC Andersen Capital receives payment from Qlife Holding for a Corporate Visibility/Digital IR subscription agreement. /Claus Thestrup 9.53 AM 10-November-2022.

Information

Qlife Holding – Presentation of Q3 interim report 2022 30 NovemberNov 2022 13:00 - 13:30
Qlife Holding – Presentation of Q3 interim report 2022 Online Event
Qlife Holding